Accretion Pharma Files FY26 Investor Presentation; Reports Strong Annual Results

Accretion Pharmaceuticals Limited has announced its audited financial results for the year ended March 31, 2026, alongside an investor/analyst presentation filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported a total income of ₹8981.76 lakh for the fiscal year, a significant increase from ₹5747.06 lakh in the previous year. Revenue from operations stood at ₹8962.71 lakh compared to ₹5737.62 lakh in the prior year, reflecting robust operational performance. The profit before tax rose to ₹1308.31 lakh from ₹976.38 lakh in the previous year, while net profit climbed to ₹966.75 lakh from ₹679.35 lakh. The basic and diluted earnings per equity share were reported at ₹9.03 for the current year.

Annual Financial Highlights

The following table summarizes the key financial figures for the year ended March 31, 2026, compared to the previous year (all figures in ₹ lakh):

Particulars: FY26 (Audited) FY25 (Audited) Revenue from Operations: 8962.71 5737.62 Total Income: 8981.76 5747.06 Total Expenses: 7673.45 4770.68 Profit Before Tax: 1308.31 976.38 Net Profit: 966.75 679.35

Half-Yearly Performance

The investor presentation provides a detailed breakdown of the company's half-yearly performance. In H2 FY26, total income from operations stood at ₹45.89 crore, an increase of 18.24% compared to ₹38.81 crore in H2 FY25. EBITDA for H2 FY26 was ₹7.88 crore, up 4.50% year-on-year, though the EBITDA margin contracted by 226 basis points to 17.17% from 19.43% in H2 FY25. Profit after tax for H2 FY26 grew 13.55% to ₹4.92 crore from ₹4.33 crore in H2 FY25.

Particulars (₹ in Crore): H2 FY26 H2 FY25 YoY% H1 FY26 Total Income from Operations: 45.89 38.81 18.24% 43.74 Total Expenditure: 38.01 31.27 21.55% 36.67 EBITDA: 7.88 7.54 4.50% 7.07 EBITDA Margin (%): 17.17% 19.43% (226 bps) 16.17% Profit Before Tax: 6.67 6.47 3.13% 6.41 Profit After Tax: 4.92 4.33 13.55% 4.75 PAT Margin (%): 10.71% 11.15% (44 bps) 10.87% EPS (₹): 4.42 5.30 (16.60%) 4.61

Multi-Year Financial Performance

The presentation also highlights the company's multi-year growth trajectory across key financial metrics (all figures in ₹ crore):

Particulars (₹ in Crore): FY26 FY25 FY24 FY23 FY22 Total Income from Operations: 89.63 57.38 33.67 29.38 22.29 Total Expenditure: 74.68 45.50 26.18 27.39 20.65 EBITDA: 14.95 11.88 7.49 1.99 1.64 EBITDA Margin (%): 16.68% 20.71% 22.25% 6.78% 7.35% Profit Before Tax: 13.08 9.76 5.76 0.14 0.10 Profit After Tax: 9.67 6.79 3.88 0.10 0.08 PAT Margin (%): 10.79% 11.84% 11.50% 0.35% 0.40% EPS (₹): 9.03 8.48 9.69 - -

Balance Sheet Overview

The presentation outlines the company's balance sheet position across five years. Shareholders' funds grew significantly to ₹54.71 crore in FY26 from ₹15.29 crore in FY25, driven by an increase in reserves and surplus to ₹43.59 crore. Total assets expanded to ₹76.66 crore in FY26 from ₹39.87 crore in FY25.

Liabilities (₹ in Crore):

Particulars: FY26 FY25 FY24 FY23 FY22 Shareholders' Funds: 54.71 15.29 5.35 3.84 3.08 Non-Current Liabilities: 1.13 1.36 7.04 2.91 2.93 Current Liabilities: 20.81 23.23 14.66 13.83 11.73 Total Equities & Liabilities: 76.66 39.87 27.05 20.58 17.74

Assets (₹ in Crore):

Particulars: FY26 FY25 FY24 FY23 FY22 Non-Current Assets: 16.06 6.33 5.46 6.05 5.86 Current Assets: 60.59 33.55 21.59 7.76 11.88 Total Assets: 76.66 39.87 27.05 20.58 17.74

Manufacturing Capabilities

The investor presentation highlights the company's manufacturing infrastructure located at Xcelon Industrial Park 1, Vasna Chacharwadi, Ahmedabad, Sanand, Gujarat. The facility holds WHO cGMP, GLP, ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications. The total installed capacity stands at 1,635 million units across multiple dosage forms, including tablets (1,000 million), capsules (450 million), oral liquids (21.75 million bottles), oral powders (153.75 million bottles and pouches), and external preparations (9 million tubes).

Dosage Form: Installed Capacity Tablets: 1,000 Mn Capsules: 450 Mn Oral Liquid: 21.75 Mn (Bottles) Oral Powder: 153.75 Mn (Bottles & Pouch) External Preparations: 9 Mn (Tubes) Total Installed Capacity: 1,635 Million

Board Appointments and Auditor Approvals

During the Board meeting held on May 8, 2026, several key appointments were approved. Ms. Bandana Kumari was appointed as HR Manager effective May 8, 2026, bringing over 14 years of experience in Human Resource Management and holding an MBA in HR from Sikkim Manipal University. The Board appointed M/s. R R Thakkar & Co., Chartered Accountants, as Internal Auditors for FY2026-27, and re-appointed M/s. Sakhiya & Co., Company Secretaries, as Secretarial Auditors for FY2026-27. The Statutory Auditors, M/s. V S S B & Associates, issued an unmodified opinion on the audited financial results.

IPO Proceeds Utilization

The company provided a statement on the utilization of proceeds from its Initial Public Offer (IPO). The total proceeds amounted to ₹2975.46 lakh. As of March 31, 2026, the total utilization of IPO proceeds was complete, with no unutilized balance remaining pending deployment for approved purposes. The funds were utilized for capital expenditure, repayment of borrowings, and funding working capital requirements.

Accretion Pharmaceuticals Limited has filed its Structured Digital Database (SDD) Compliance Certificate with the National Stock Exchange of India Limited, pertaining to the financial year ended 31st March, 2026. The certificate was submitted on 7th May, 2026, by Company Secretary and Compliance Officer Roshni Shah, pursuant to Regulation 3(5) and 3(6) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Certificate Issued by Practicing Company Secretaries

The SDD Compliance Certificate was issued by CS Nimish Sakhiya, Proprietor of M/s. Sakhiya & Co., Practicing Company Secretaries, based in Rajkot. The certificate was prepared on the basis of details and documents provided by the company and carries the ICSI Firm Unique Code S2019GJ689300 and ICSI Peer Review No. 4057/2023.

Key Compliance Parameters Confirmed

The certificate confirms that Accretion Pharmaceuticals has met all requisite compliance parameters under the PIT Regulations. The following aspects of SDD compliance were certified:

The company has a Structured Digital Database in place

Access controls exist to regulate who can access the SDD

All Unpublished Price Sensitive Information (UPSI) disseminated in the previous quarter has been captured in the database

The system has captured the nature of UPSI along with date and time

The database is maintained internally with an audit trail

The database is non-tamperable and capable of maintaining records for 8 years

Event Capture and Non-Compliance Status

The table below summarises the event capture and compliance status for the quarter ended 31st March, 2026:

Parameter: Details Events Required to be Captured: 2 Events Actually Captured: 2 Non-Compliance Observed: Not Applicable Remedial Action Required: Not Applicable

The certifying company secretary confirmed that no non-compliance was observed during the quarter, and accordingly, no remedial actions were required.

Filing Details

The compliance certificate was digitally signed by both Roshni Shah, Company Secretary and Compliance Officer of Accretion Pharmaceuticals, and CS Nimish Sakhiya on 7th May, 2026. The submission was addressed to the Corporate Relations Department of the National Stock Exchange of India Limited.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.